CDSCO Panel Approves Updated Prescribing Information for AstraZeneca's Rosuvastatin (Crestor) Written By Dr. Divya Colin8 Jun 2025 12:43 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted approval for the updated...
AstraZeneca Calquence based regimens approved in EU for previously untreated chronic lymphocytic leukaemia Written By Ruchika Sharma6 Jun 2025 12:28 PM ISTA fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has received...
Justify Sample Size Hike in FDC Trial of Zibotentan-Dapagliflozin, CDSCO Panel Tells AstraZeneca Written By Dr. Divya Colin31 May 2025 6:04 PM ISTNew Delhi: Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject Expert...
AstraZeneca Imfinzi recommended for approval in EU for adults with muscle-invasive bladder cancer Written By Ruchika Sharma29 May 2025 2:15 PM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the...
AstraZeneca Pharma India gets CDSCO Panel nod for Anti-cancer Drug Osimertinib Tablets 40 mg and 80 mg Written By Dr. Divya Colin20 May 2025 6:00 PM ISTNew Delhi: With the condition of conducting a Phase IV clinical trial study, the Subject Expert Committee (SEC) functional under the Central Drug...
AstraZeneca successfully completes acquisition of EsoBiotec Written By Ruchika Sharma20 May 2025 12:27 PM ISTAstraZeneca has successfully completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated...
AstraZeneca Trixeo Aerosphere approved in UK as inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential Written By Ruchika Sharma13 May 2025 10:30 AM ISTCambridge: AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF), already licensed for the treatment of...
AstraZeneca Calquence plus chemoimmunotherapy approved in EU for 1st-line mantle cell lymphoma Ruchika Sharma7 May 2025 12:30 PM ISTCambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the...
Medical Bulletin 05/ May/ 2025 Dr. Garima Soni5 May 2025 3:00 PM ISTHere are the top medical news for the day:Too Much Chicken? New Research Finds Link to Increased Risk of Early DeathA recent study published in the...
AI-Enabled X-Rays Help Detect Lung Cancer Risk in 50,000 Patients Worldwide: Study Shows Dr. Garima Soni5 May 2025 8:30 AM ISTAstraZeneca, in partnership with health-tech company Qure.ai, has successfully completed over 5 million artificial intelligence (AI)-enabled chest...
AstraZeneca Breztri met primary endpoints in Phase III trials in asthma Written By Ruchika Sharma4 May 2025 10:30 AM ISTAstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that...
Fixed duration Calquence based regimens recommended for EMA Committee for chronic lymphocytic leukaemia: AstraZenaca Written By Ruchika Sharma30 April 2025 1:30 PM ISTAstraZeneca has announced that a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without...
